July 18, 2012
The human rhinovirus, otherwise known as the common cold, is usually a fairly minor inconvenience for its human hosts. But the symptoms are far more serious for those suffering from asthma and chronic obstructive pulmonary disease (COPD). Today roughly 70 percent of heightened asthma symptoms are linked to the common cold. Over 50 percent of those affected eventually require hospitalization. It is also responsible for sending more than 35 percent of COPD sufferers to hospitals each year.
To help the at-risk population, Biota Holdings Ltd., a Melbourne-based company is developing an antiviral drug. This has led members from St. Vincent’s Institute of Medical Research (SVI) and the University of Melbourne to research how the drug works against the rhinovirus.
In a press release describing the work, scientists are using supercomputing simulations as a basis for revealing the drug’s efficacy. Professor Michael Parker, who leads the research team, explained the basic mechanics behind the new compound. “Our recently published work with Biota shows that the drug binds to the shell that surrounds the virus, called the capsid. But that work doesn’t explain in precise detail how the drug and other similar acting compounds work,” he said.
Part of the team’s study involved creating a 3D model of the rhinovirus. It was simulated using the recently deployed Avoca supercomputer at Melbourne University. An IBM Blue Gene/Q machine, the system has 65,536, 1.6GHz power cores with 65 terabytes of memory. At 838 peak teraflops (690 teraflops Linpack), Avoca is the fastest computer in Australia and ranks 31st on the June 2012 TOP500 list.
Parker said that supercomputers like Avoca have enabled scientists to study how drugs function at a molecular level. The new system can now simulate the entire rhinovirus in useful time frames, which in turn can accelerate the discovery and development of new treatments. Prior to the Avoca’s installation, researchers only had the capability to run simulations on portions of the virus.
If the research proves successful, it could reduce the lethality of the common cold for at-risk populations while reducing associated medical costs. Dr. John Wagner, the manager at IBM’s Research Collaboratory for Life Sciences in Melbourne, noted that simulations like this are going to drive life science research moving forward. “This is the way we do biology in the 21st Century,” he said.
Contributing commentator, Andrew Jones, offers a break in the news cycle with an assessment of what the national "size matters" contest means for the U.S. and other nations...
Read more...
Today at the International Supercomputing Conference in Leipzing, Germany, Jack Dongarra presented on a proposed benchmark that could carry a bit more weight than its older Linpack companion. The high performance conjugate gradient (HPCG) concept takes into account new architectures for new applications, while shedding the floating point....
Read more...
Not content to let the Tianhe-2 announcement ride alone, Intel rolled out a series of announcements around its Knights Corner and Xeon Phi products--all of which are aimed at adding some options and variety for a wider base of potential users across the HPC spectrum. Today at the International Supercomputing Conference, the company's Raj....
Read more...
05/10/2013 | Cleversafe, Cray, DDN, NetApp, & Panasas | From Wall Street to Hollywood, drug discovery to homeland security, companies and organizations of all sizes and stripes are coming face to face with the challenges – and opportunities – afforded by Big Data. Before anyone can utilize these extraordinary data repositories, however, they must first harness and manage their data stores, and do so utilizing technologies that underscore affordability, security, and scalability.
04/15/2013 | Bull | “50% of HPC users say their largest jobs scale to 120 cores or less.” How about yours? Are your codes ready to take advantage of today’s and tomorrow’s ultra-parallel HPC systems? Download this White Paper by Analysts Intersect360 Research to see what Bull and Intel’s Center for Excellence in Parallel Programming can do for your codes.
Join HPCwire Editor Nicole Hemsoth and Dr. David Bader from Georgia Tech as they take center stage on opening night at Atlanta's first Big Data Kick Off Week, filmed in front of a live audience. Nicole and David look at the evolution of HPC, today's big data challenges, discuss real world solutions, and reveal their predictions. Exactly what does the future holds for HPC?
Join our webinar to learn how IT managers can migrate to a more resilient, flexible and scalable solution that grows with the data center. Mellanox VMS is future-proof, efficient and brings significant CAPEX and OPEX savings. The VMS is available today.